+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alzheimer's Disease Drugs Market - Global Forecast 2026-2032- Product Image
Alzheimer's Disease Drugs Market - Global Forecast 2026-2032- Product Image
New

Alzheimer's Disease Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4905145
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders in the Alzheimer’s Disease Drugs Market face persistent complexity—balancing innovation, regulatory shifts, and evolving care models to drive both patient impact and sustained business growth. In this environment, strategic clarity and actionable market knowledge are essential for informed leadership.

Market Snapshot: Alzheimer’s Disease Drugs Market Outlook

The global Alzheimer’s Disease Drugs Market expanded from USD 5.22 billion in 2025 to USD 5.74 billion in 2026, with a projected compound annual growth rate (CAGR) of 10.42%. By 2032, it is expected to reach USD 10.46 billion. This growth is influenced by growing demand for next-generation therapies, strengthening requirements from payers for proven healthcare value, and an ongoing transition in distribution models to address specific regional regulations and variable patient access needs. Pharmaceutical manufacturers and healthcare organizations are actively recalibrating strategies to capture emerging opportunities and adapt to shifting policy frameworks.

Scope & Segmentation

  • Therapeutic Class: Covers both established and advanced drug categories, including amyloid beta-targeting agents, cholinesterase inhibitors, beta-secretase inhibitors, and NMDA receptor antagonists. This segment supports treatment diversity and addresses multiple disease pathways.
  • Drug Type: Encompasses branded therapies and generics, focusing on lifecycle management and flexible entry paths to stay competitive amid changing regulations and heightened pressure for innovation.
  • Formulation Strategy: Incorporates intravenous infusions, subcutaneous injections, and oral capsules or tablets, reflecting the strategic emphasis on versatile delivery formats to improve care across settings and boost patient adherence.
  • Distribution Pathways: Includes hospital pharmacies, retail channels, and online platforms, each with particular compliance and access challenges, highlighting the necessity for efficient delivery systems and consistent adherence protocols.
  • End-User Settings: Addresses hospitals, ambulatory clinics, and homecare environments, emphasizing the importance of supportive infrastructure, training for staff and caregivers, and seamless integration of chronic care solutions.
  • Regional Dynamics: Highlights distinct market patterns and stakeholder expectations in Americas, Europe–Middle East–Africa, and Asia-Pacific, each requiring tailored commercialization initiatives, nuanced access programs, and focused regulatory approaches to achieve optimal launch and sustained uptake.
  • Technology Solutions: Features the integration of digital biomarkers, decentralized clinical trial support, advanced infusion technologies, and improved diagnostic capabilities, all contributing to robust evidence generation and targeted patient identification.

Key Takeaways for Alzheimer’s Disease Drugs Market Strategy

  • Strategic execution depends on seamless alignment of clinical data, stakeholder partnerships, and agile manufacturing to ensure products remain timely and compliant within varied regulatory landscapes.
  • Investment in biomarker technologies, evidence from longitudinal studies, and analysis of real-world outcomes are key to advancing adoption and refining both research and market access pipelines.
  • Expansion of decentralized clinical trials and digital health tools extends patient outreach and supports the shift to community-based and homecare care models.
  • Resilient supply chains rely on supplier diversification, domestic capacity building, and dual-sourcing strategies, reducing exposure to procurement risks and evolving policies impacting the sector.
  • Collaborations that unify drug development, diagnostics integration, and optimized distribution create a more efficient patient pathway and enhance long-term adoption and relevance in the marketplace.
  • Portfolio management and market segmentation—guided by comprehensive, data-driven analysis—can refine launch strategies and sequence commercialization to match new care delivery trends.

Tariff Impact: Navigating U.S. Policy Changes in Alzheimer’s Supply Chains

Recent policy adjustments in the United States have altered the tariff landscape for Alzheimer’s drugs, adding complexities for procurement and distribution. Companies are responding by broadening supplier pools, strengthening domestic manufacturing capacity, and implementing dual-sourcing models. Healthcare providers are adjusting inventory planning and updating pricing frameworks, while payers pursue long-term contracts to help maintain uninterrupted patient access and control supply chain costs and volatility.

Methodology & Data Sources

This report synthesizes structured interviews with clinical experts, regulatory officials, and payer representatives, alongside a systematic review of the literature and case analysis of supply chain management. Each key finding is validated through multi-stage expert review, ensuring rigorous and actionable guidance for market stakeholders.

Why This Report Matters

  • Enables strategic investment and operational decisions for senior leaders navigating the Alzheimer’s Disease Drugs Market.
  • Delivers current insights into regulatory movements, payer priorities, and technology adoption across all significant regions, supporting competitive planning and advanced risk mitigation.
  • Provides actionable recommendations for supply chain resilience, effective portfolio management, and commercialization tailored to advances in care delivery and technology use.

Conclusion

Sustained market leadership in Alzheimer’s therapeutics demands robust clinical validation, flexible operations, and adaptive commercialization. Organizations employing evidence-driven strategies and supply chain resilience are best positioned for meaningful impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Alzheimer's Disease Drugs Market, by Drug Class
8.1. Amyloid Beta-Targeting Agents
8.1.1. Amyloid Beta Antibodies
8.1.2. Beta-Secretase (BACE) Inhibitors
8.2. Cholinesterase Inhibitors
8.3. NMDA Receptor Antagonists
9. Alzheimer's Disease Drugs Market, by Drug Type
9.1. Branded Drugs
9.2. Generic Drugs
10. Alzheimer's Disease Drugs Market, by Formulation
10.1. Injectable
10.1.1. Intravenous Infusion
10.1.2. Subcutaneous Injection
10.2. Oral
10.2.1. Capsule
10.2.2. Tablet
11. Alzheimer's Disease Drugs Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Alzheimer's Disease Drugs Market, by End User
12.1. Clinics
12.2. Homecare
12.3. Hospitals
13. Alzheimer's Disease Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Alzheimer's Disease Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Alzheimer's Disease Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Alzheimer's Disease Drugs Market
17. China Alzheimer's Disease Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc
18.6. AC Immune SA
18.7. Amgen Inc
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. Biogen Inc
18.11. Daiichi Sankyo Company Limited
18.12. Eisai Co Ltd
18.13. Eli Lilly and Company
18.14. GlaxoSmithKline PLC
18.15. H. Lundbeck A/S
18.16. Johnson & Johnson
18.17. Lupin Pharmaceuticals Inc
18.18. Merck & Co Inc
18.19. Novartis AG
18.20. Otsuka Pharmaceutical Co Ltd
18.21. Pfizer Inc
18.22. Roche Holding AG
18.23. Sanofi S.A
18.24. Teva Pharmaceutical Industries Ltd
List of Figures
FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BETA-SECRETASE (BACE) INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BETA-SECRETASE (BACE) INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BETA-SECRETASE (BACE) INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 111. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. EUROPE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 125. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 126. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 127. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 128. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 129. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 143. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 145. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 146. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 147. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 148. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. ASEAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 152. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 153. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 154. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 155. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 156. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 157. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. GCC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 170. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 171. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 172. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 173. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 174. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 175. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. BRICS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 180. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 181. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 182. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 183. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 184. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. G7 ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 188. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 189. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 190. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 191. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 192. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 193. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. NATO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2032 (USD MILLION)
TABLE 208. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 209. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 210. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 211. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 212. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Alzheimer's Disease Drugs market report include:
  • AbbVie Inc
  • AC Immune SA
  • Amgen Inc
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc
  • Daiichi Sankyo Company Limited
  • Eisai Co Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc
  • Merck & Co Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi S.A
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.74 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.46 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Alzheimer's Disease Drugs - Global Strategic Business Report - Product Image

Alzheimer's Disease Drugs - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Alzheimer's Therapeutics Market - Global Forecast 2026-2032 - Product Image

Alzheimer's Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Medications for Alzheimer's Disease Market - Global Forecast 2026-2032 - Product Image

Medications for Alzheimer's Disease Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Alzheimer's Treatment Market Report and Forecast 2025-2034 - Product Image

Alzheimer's Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Alzheimer's Disease Treatment Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Alzheimer's Disease Treatment Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 89 Pages
  • Global
From

About the Alzheimer's Disease Drugs Market

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone. The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.